Open-Label Study to Determine the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma, Followed by an Expansion Phase at the Maximum-Tolerated Dose (MTD) - A Phase II Study
Phase of Trial: Phase II
Latest Information Update: 20 Sep 2017
At a glance
- Drugs Ixazomib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors SCRI Development Innovations
- 15 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Dec 2017.
- 05 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Aug 2017.
- 22 Aug 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.